TAO Synergies Inc.
Business
TAO Synergies Inc. is a biopharmaceutical company developing therapeutics that activate Protein Kinase C epsilon (PKCε) to restore synapses and prevent neuronal loss for neurodegenerative and cognitive disorders. Its main product candidates include Bryostatin‑1 (including synthetic bryostatin and bryologs) and PUFA analogs, supported by clinical trials, IND filings, and technology licenses. The company organizes around clinical development, intellectual property and licensing, research collaborations and strategic investments. It pursues regulatory pathways and commercial opportunities primarily across North America, Europe and Japan through clinical sites, research partners and licensing channels.
Summary from filing dated 2025-03-27
Financials
Consolidated Statement of Income
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | — | — | |
| REVENUES: | — | — | |
| Revenues from TAO staking | 299,061 | 0 | |
| OPERATING EXPENSES: | — | — | |
| Research and development | 322,225 | 2 | |
| General and administrative | 9 | 5 | |
| TOTAL OPERATING EXPENSES | 9 | 7 | |
| OPERATING LOSS | −9 | −7 | |
| OTHER INCOME: | — | — | |
| Interest income | 442,913 | 1 | |
| Share of net loss in equity investment | — | −44,525 | |
| Loss on write-off of available for debt security | — | −2 | |
| Loss on write-off of equity investment | — | 517,877 | |
| Warrant issuance costs | 2 | 618,375 | |
| Unrealized loss on digital assets | 11 | — | |
| Change in fair value of Yuma partnership investments | −303,046 | — | |
| Loss on issuance of Preferred Stock | 758,691 | 4 | |
| Change in fair value of warrant liability | 12 | 829,000 | |
| Change in fair value of derivative liability | 6 | 1 | |
| TOTAL OTHER INCOME | −20 | −6 | |
| Net income before income taxes | −29 | −13 | |
| Provision for income taxes | 0 | 0 | |
| Net income | −29 | −13 | |
| Preferred Stock dividends | 338,359 | 789,909 | |
| Net income attributable to common stockholders | −29 | −14 | |
| Change in fair value of available for sale debt security | — | 4,800 | |
| Comprehensive loss | −29 | −14 | |
| PER SHARE DATA: | — | — | |
| Basic income per common share (in dollars per share) | −8.81 | −10.99 | |
| Fully diluted income per common share (in dollars per share) | −8.81 | −10.99 | |
| Basic weighted average common shares outstanding (in shares) | 3 | 1 | |
| Fully diluted weighted average common shares outstanding (in shares) | 3 | 1 |
Consolidated Balance Sheet
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| CONDENSED CONSOLIDATED BALANCE SHEETS | — | — | |
| ASSETS | — | — | |
| CURRENT ASSETS | — | — | |
| Cash and cash equivalents | 5 | 18 | |
| Digital assets | 18 | — | |
| Prepaid expenses and other current assets | 2 | 64,633 | |
| TOTAL CURRENT ASSETS | 25 | 18 | |
| Fixed assets, net of accumulated depreciation | 9,309 | 12,925 | |
| Yuma Partnership investments | 446,954 | — | |
| TOTAL ASSETS | 26 | 18 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | — | — | |
| CURRENT LIABILITIES | — | — | |
| Accounts payable | 1 | 317,287 | |
| Accrued expenses | 638,516 | 696,980 | |
| TOTAL CURRENT LIABILITIES | 2 | 1 | |
| Warrant liability | 9,000 | 4 | |
| Derivative liability | 2 | 6 | |
| TOTAL LIABILITIES | 4 | 11 | |
| Commitments and contingencies | — | — | |
| Convertible redeemable preferred stock, value | 846,701 | 912,830 | |
| STOCKHOLDERS' EQUITY | — | — | |
| Common stock - 150,000,000 shares authorized, $0.0001 par value; 7,471,931 shares issued and outstanding as of March 31, 2026 and 7,448,343 shares issued and outstanding as of December 31, 2025. | 746 | 137 | |
| Additional paid-in capital | 97 | 53 | |
| Accumulated other comprehensive income | 5,702 | 5,702 | |
| Accumulated deficit | −76 | −47 | |
| TOTAL STOCKHOLDERS' EQUITY | 21 | 6 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 26 | 18 |
Consolidated Statement of Cash Flows
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | — | — | |
| CASH FLOW USED IN OPERATING ACTIVITIES | — | — | |
| Net income | −29 | −13 | |
| Adjustments to reconcile net loss to net cash used by operating activities | — | — | |
| Stock based compensation | 1 | 25,407 | |
| Non-cash revenue from digital assets | 299,061 | — | |
| Unrealized loss on digital assets | 11 | — | |
| Change in fair value of Yuma partnership investments | −303,046 | — | |
| Warrant issuance costs | 2 | 618,375 | |
| Loss on issuance of Convertible Preferred Stock | 758,691 | 4 | |
| Change in fair value of warrant liability | 12 | 829,000 | |
| Change in fair value of derivative liability | 6 | 1 | |
| Share of net loss in equity investment | — | −44,525 | |
| Loss on write-off of available for debt security | — | −2 | |
| Loss on write-off of equity investment | — | 517,877 | |
| Consulting services paid by issuance of common stock | 118,116 | 118,001 | |
| Consulting services paid by issuance of warrants | 573,547 | — | |
| Depreciation expense | 3,616 | 5,580 | |
| Change in assets and liabilities: | — | — | |
| Decrease (increase) in prepaid expenses and other current assets | 379,826 | −368,128 | |
| (Decrease) in accounts payable | 858,036 | −127,346 | |
| (Decrease) in accrued expenses | −58,464 | 261,089 | |
| Total adjustments | 22 | 8 | |
| Net Cash Used in Operating Activities | −6 | −5 | |
| CASH FLOWS USED IN INVESTING ACTIVITIES | — | — | |
| Purchase of available for sale debt security | — | 1 | |
| Yuma Partnership investments | 750,000 | — | |
| Purchase of crypto currency | 28 | — | |
| Net Cash Used in Investing Activities | −29 | −1 | |
| CASH FLOWS FROM FINANCING ACTIVITIES | — | — | |
| Proceeds from investor warrant exercises | 10 | — | |
| Net proceeds from Convertible Preferred Stock offering | 15 | 4 | |
| Redemption of Convertible Preferred Stock | 1 | 9 | |
| Dividends on Preferred Stock | 262,087 | 950,918 | |
| Net Cash Used in Financing Activities | 23 | −5 | |
| NET DECREASE IN CASH AND EQUIVALENTS | −12 | −11 | |
| CASH AND EQUIVALENTS AT END OF PERIOD | — | — | |
| CASH AND EQUIVALENTS AT END OF PERIOD | — | — | |
| DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | — | — | |
| Issuance of Common Stock for Series B Convertible Preferred Stock installment conversions | 5 | 1 | |
| Accretion of Convertible Preferred Stock to redemption value | 5 | 7 | |
| Warrant liability upon issuance of Convertible Preferred stock | 5 | 3 | |
| Reclassification of warrant liability | 21 | — | |
| Derivative liability upon issuance of Convertible Preferred stock | 8 | 6 | |
| Reclassification of derivative liability | 6 | — | |
| Issuance of Consultant Warrants | 2 | — | |
| Change in fair value of available for sale debt security | — | 4,800 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is TAO Synergies Inc.'s CIK number?
TAO Synergies Inc.'s SEC CIK number is 0001571934 (1571934). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find TAO Synergies Inc.'s SEC filings?
All of TAO Synergies Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did TAO Synergies Inc. last report earnings?
TAO Synergies Inc. (TAOX) most recently filed an earnings 8-K with the SEC on Mar 7, 2023, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-23-029338). This is TAO Synergies Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is TAO Synergies Inc.'s most recent earnings 8-K?
TAO Synergies Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 7, 2023 under accession 0001104659-23-029338. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View TAO Synergies Inc.'s latest earnings 8-K →
Look up any company's CIK number →